ArticleCancers2024
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study.
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Safety and Management of Targeted Therapies for Relapsed/Refractory Chronic Lymphocytic Leukemia.Drug safety · 2026Review
- Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience.British journal of haematology · 2026Observational
- Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.Cancers · 2026Article
- Real-world disease characteristics and frontline treatments used in chronic lymphocytic leukaemia in Bulgaria: An observational cohort study (DESCRIBE).The Journal of international medical research · 2026Observational
- First-Line Treatment of Chronic Lymphocytic Leukemia in Italy: Real-World Evidence on Utilization, Outcomes, and Healthcare Costs.ClinicoEconomics and outcomes research : CEOR · 2026Article
- Fixed-duration ibrutinib-venetoclax for first-line treatment of patients with chronic lymphocytic leukemia: the REALITY-WW prospective real-world study cohort.Future oncology (London, England) · 2025Observational
- Current and future landscape of Bruton tyrosine kinase inhibitors in allergy.The Journal of allergy and clinical immunology · 2025Review
- Article
- Cause-Specific Mortality and Prognostic Impact of Comorbidity in Japanese Patients With Chronic Lymphocytic Leukemia.Cancer medicine · 2025Article
- Real world outcomes with Ibrutinib monotherapy in chronic lymphocytic leukemia: a single center experience.Medicine and pharmacy reports · 2025Article
- Severe atypical skin disease in two patients with CLL/SLL after BTKi treatment - a case report and literature review.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors at 20 institutions in 2 countries.
Francesca Romana MauroEmatologia, Sapienza Università di Roma, 00185 Roma, Italy.ORCID 0000-0003-2425-9474
Potito Rosario ScalzulliOspedale "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Lydia ScarfòUniversità Vita-Salute San Raffaele, 20132 Milano, Italy.
Carla MinoiaHematology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.
Roberta MurruHematology and Stem Cell Transplantation Unit, Ospedale Oncologico A. Businco, ARNAS G. Brotzu, 09134 Cagliari, Italy.ORCID 0000-0001-9792-9542
Paolo SportolettiSezione di Ematologia, Università degli Studi di Perugia, 06123 Perugia, Italy.ORCID 0000-0002-5630-9862
Ferdinando FrigeriAORN "Sant'Anna e San Sebastiano", 81100 Caserta, Italy.
Francesco AlbanoHematology and Stem Cell Transplantation Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", 70121 Bari, Italy.ORCID 0000-0001-7926-6052
Nicola Di RenzoUOC Ematologia e Trapianto di Cellule Staminali-PO "Vito Fazzi" ASL Lecce, 73100 Lecce, Italy.
Alessandro SannaAOU Careggi, 50121 Firenze, Italy.
Luca LaurentiPoliclinico A. Gemelli, 00168 Roma, Italy.ORCID 0000-0002-8327-1396
Massimo MassaiaSC Ematologia-AO S. Croce e Carle, 12100 Cuneo, Italy.
Ramona CassinFondazione IRCCS Cà Granda Ospedale Maggiore Policlinico of Milan, 20122 Milano, Italy.
Marta CosciaDipartimento di Biotecnologie Molecolari e Scienze per la Salute, Università degli Studi di Torino, 10124 Torino, Italy.ORCID 0000-0003-2123-7675
Caterina PattiUOC Oncoematologia, Ospedali Riuniti Villa Sofia-Cervello, 90146 Palermo, Italy.
Elsa PenneseUOC Ematologia Clinica, ASL Pescara, 65124 Pescara, Italy.
Agostino TafuriEmatologia, AOU Sant'Andrea, Sapienza Università di Roma, 00185 Roma, Italy.
Annalisa ChiarenzaUOC Ematologia, AOU Policlinico G.Rodolico-San Marco, 95123 Catania, Italy.
Piero GalieniUOC Ematologia e Terapia Cellulare, Ospedale Mazzoni, 63100 Ascoli Piceno, Italy.
Omar PerbelliniUOC Ematologia, Azienda ULSS 8 Berica, 36100 Vicenza, Italy.
Carmine SelleriHematology and Bone Marrow Transplant Center, Department of Medicine and Surgery, University of Salerno, 84081 Salerno, Italy.ORCID 0000-0002-5861-8984
Catello CalifanoUOC Ematologia, PO Andrea Tortora-Pagani, 84016 Pagani, Italy.
Felicetto FerraraAORN Antonio Cardarelli, 80131 Napoli, Italy.
Antonio CuneoDepartment of Medical Science, Università degli Studi di Ferrara, 44121 Ferrara, Italy.ORCID 0000-0003-2001-1308
Marco MurinedduEmatologia, Ospedale San Francesco ASL Nuoro, 08100 Nuoro, Italy.
Gaetano PalumboSC Ematologia, AOU Policlinico Foggia, 71122 Foggia, Italy.
Ilaria ScortechiniAzienda Ospedaliero Universitaria delle Marche, 60126 Ancona, Italy.
Alessandra TedeschiDivisione di Ematologia, ASST GOM Niguarda, 20162 Milano, Italy.
Livio TrentinDipartimento di Medicina, UOC Ematologia, Università di Padova, 35122 Padova, Italy.ORCID 0000-0003-1222-6149
Marzia VarettoniDivisione di Ematologia, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.ORCID 0000-0001-7304-1629
Fabrizio PaneDivision of Hematology, Department of Clinical Medicine and Surgery, Università di Napoli Federico II, 80131 Napoli, Italy.ORCID 0000-0003-2563-4125
Anna Marina LiberatiAO Santa Maria, Università degli Studi Di Perugia, 05100 Terni, Italy.ORCID 0000-0002-3686-3188
Francesco MerliEmatologia AUSL-IRCCS Reggio Emilia, 42123 Reggio Emilia, Italy.
Lucia MorelloIRCCS Humanitas Research Hospital-Humanitas Cancer Center, 20089 Rozzano, Italy.
Gerardo MusuracaIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.ORCID 0000-0003-1947-1032
Monica TaniHaematology Unit, Ospedale S. Maria delle Croci, 48121 Ravenna, Italy.
Adalberto IbaticiIRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Giulia RegazzoniJohnson & Johnson Innovative Medicine, 20126 Milano, Italy.
Michele Di CandiaJohnson & Johnson Innovative Medicine, 20126 Milano, Italy.
Maria PalmaJohnson & Johnson Innovative Medicine, 20126 Milano, Italy.
Danilo ArientiJohnson & Johnson Innovative Medicine, 20126 Milano, Italy.
Stefano MolicaDipartimento Onco-Ematologico, Azienda Ospedaliera Pugliese-Ciaccio, 88100 Catanzaro, Italy.ORCID 0000-0003-2795-6507
Johnson & Johnson (Italy) · ITUniversity of Perugia · ITAgostino Gemelli University Polyclinic · ITAULSS 2 Marca Trevigiana · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITAzienda Ospedaliera G. Brotzu · ITAzienda Ospedaliera Sant'Andrea · ITAzienda Ospedaliero-Universitaria Careggi · ITAzienda Ospedaliero Universitaria Ospedali Riuniti · ITAzienda Sanitaria Ospedaliera S.Croce e Carle Cuneo · ITAzienda Sanitaria Unità Locale di Reggio Emilia · ITAzienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ITAzienda USL di Pescara · ITCasa Sollievo della Sofferenza · ITCastle Hill Hospital · GBFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITIRCCS Humanitas Research Hospital · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITIstituto Tumori Bari · ITOspedale Antonio Cardarelli · IT
Funding
Johnson & Johnson N/A
Abstract
Real-world data in clinical practice are needed to confirm the efficacy and safety that ibrutinib has demonstrated in clinical trials of patients with chronic lymphocytic leukemia (CLL). We described the real-world persistence rate, patterns of use, and clinical outcomes in 309 patients with CLL receiving single-agent ibrutinib in first line (1L,
Indexed as
chronic lymphocytic leukemiaclinical outcomeseffectivenessibrutinibreal-world evidenceretention
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.